Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | MMP2 | P08253 | 2/20 | 0.49 |
| ▸ | MMP9 | P14780 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
| ▸ | MMP3 | P08254 | 1/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30191451 | 1.00 | BTK (0.50) | BTKCA1CA2MMP2MMP9 | |
| SCHEMBL555256 | 1.00 | BTK (0.50) | BTKCA1CA2MMP2MMP9 | |
| SCHEMBL1693182 | 1.00 | BTK (0.50) | BTKCA1CA2MMP2MMP9 | |
| SCHEMBL3343104 | 1.00 | BTK (0.50) | BTKCA1CA2MMP2MMP9 | |
| SCHEMBL3344958 | 1.00 | BTK (0.50) | BTKCA1CA2MMP2MMP9 | |
| SCHEMBL555255 | 1.00 | BTK (0.50) | BTKCA1CA2MMP2MMP9 | |
| SCHEMBL16125648 | 1.00 | BTK (0.50) | BTKCA1CA2MMP2MMP9 | |
| SCHEMBL1045289 | 1.00 | BTK (0.50) | BTKCA1CA2MMP2MMP9 | |
| SCHEMBL21032211 | 1.00 | BTK (0.50) | BTKCA1CA2MMP2MMP9 | |
| SCHEMBL23463705 | 0.98 | BTK (0.49) | BTKCA1CA2MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113493398-B | Preparation method of N-Boc-trans-cyclohexanediamine | 中车长春轨道客车股份有限公司 | 2023-04-14 | — | — | CN | claimed |
| CN-113999142-B | Preparation method of chiral N-Boc-trans-1, 2-cyclohexanediamine | 蚌埠中实化学技术有限公司 | 2023-01-24 | — | — | CN | claimed |
| CN-113999142-A | Preparation method of chiral N-Boc-trans-1, 2-cyclohexanediamine | 蚌埠中实化学技术有限公司 | 2022-02-01 | — | — | CN | claimed |
| WO-2025045758-A1 | ANTIBODY-DRUG CONJUGATES BASED ON MOLECULAR GLUE DEGRADERS AND USES THEREOF | MABLINK BIOSCIENCE (FR) | 2025-03-06 | — | — | WO | disclosed |
| WO-2025045761-A1 | MOLECULAR GLUE DEGRADERS AND USES THEREOF | MABLINK BIOSCIENCE (FR) | 2025-03-06 | — | — | WO | disclosed |
| EP-4512427-A1 | ANTIBODY-DRUG CONJUGATES BASED ON MOLECULAR GLUE DEGRADERS AND USES THEREOF | Mablink Bioscience (FR) | 2025-02-26 | — | — | EP | disclosed |
| EP-4512806-A1 | MOLECULAR GLUE DEGRADERS AND USES THEREOF | Mablink Bioscience (FR) | 2025-02-26 | — | — | EP | disclosed |
| CN-119499407-A | Fe-based T7 peptide targeted brain glioma micromolecular magnetic resonance contrast agent and preparation and synthesis method and application thereof | 中国科学院精密测量科学与技术创新研究院 | 2025-02-25 | — | — | CN | disclosed |
| US-20240383914-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2024-11-21 | — | — | US | disclosed |
| US-12065446-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | JANSSEN PHARMACEUTICA NV (BE) | 2024-08-20 | — | — | US | disclosed |
| US-20240262830-A1 | IRE1A MODULATORS AND USES THEREOF | NIMBUS IASO, INC. | 2024-08-08 | — | — | US | disclosed |
| US-20030119855-A1 | Heterocycle derivatives and drugs | NIPPON SHINYAKU CO., LTD. (JP) | 2003-06-26 | — | — | US | disclosed |
| EP-1306372-A1 | HETEROCYCLE DERIVATIVES AND DRUGS | Nippon Shinyaku Co., Ltd. (JP) | 2003-05-02 | — | — | EP | disclosed |
| US-20030004151-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-02 | — | — | US | disclosed |
| EP-1270557-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
| US-6201103-B1 | MONOMERS HAVE (2-AMINOETHYL)GLYCINE BACKBONE; POLYMERASE CHAIN REACTION AMPLIFICATIONS; DETECTION OF POINT MUTATIONS; DIAGNOSIS | Nielsen, Peter E. (DK) | 2001-03-13 | — | — | US | disclosed |
| US-5977296-A | MONOMERS WITH ALIPHATIC CYCLIC STRUCTURE IN THE BACKBONE; FOR INCREASED CONFORMATION RESTRICTION LEADING TO INCREASED BINDING AFFINITY AND SPECIFICITY; FOR DETECTING POINT MUTATIONS, FOR SUPPRESSING WILD TYPE GENES IN AMPLIFICATION | NIELSEN, PETER E. (DK) | 1999-11-02 | — | — | US | disclosed |
| EP-0888115-A1 | IRON COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | MONSANTO COMPANY (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997033588-A9 | IRON COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | — | 1997-11-06 | — | — | WO | disclosed |
| WO-1997033588-A1 | IRON COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | MONSANTO COMPANY (US) | 1997-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12065446-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | ABL1, BTK, LYN | BTK 2/4885CA1 4319/4885CA2 3199/4885 |
| US-20030004151-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCL2 | BTK 3233/4885CA1 1194/4885CA2 1252/4885 |
| US-20240262830-A1 | IRE1A MODULATORS AND USES THEREOF | XBP1, HSPA5, ERN2 | BTK 2672/4885CA1 4808/4885CA2 4714/4885 |
| US-20030119855-A1 | Heterocycle derivatives and drugs | OPRL1, OPRK1, OPRD1 | BTK 673/4885CA1 2568/4885CA2 843/4885 |
| US-20240383914-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | ABL1, BTK, MYLK2 | BTK 2/4885CA1 4239/4885CA2 3053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.